中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

465 records (took 0.077 seconds)

    Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
    33.
    发明申请
    Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt 失效
    5- [4- [2-（N-甲基-N-（2-吡啶基）氨基）乙氧基]苄基]噻唑烷-2,4-二酮马来酸盐的水合物

    公开(公告)号：US20040097553A1

    公开(公告)日：2004-05-20

    申请号：US10692544

    申请日：2003-10-24

    Applicant: SmithKline Beecham p.l.c.

    Inventor： Michael John Sasse ,  Paul David James Blackler ,  David C. Lee

    IPC: C07D43/02 ,  A61K031/4439

    CPC classification number: C07D417/12

    Abstract: A hydrate of 5-null4-null2-(N-methyl-N-(2-pyridyl)amino)ethoxynullbenzylnullthiazolidine-2,4-dione, maleic acid salt, characterized in that it: (i) comprises water in the range of from 0.2 to 1.1% w/w; and (ii) provides an infrared spectrum containing peaks at 764 and 579 cmnull1; and/or (iii) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in FIG. II; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound or composition in medicine.

    Abstract translation: 5- [4- [2-（N-甲基-N-（2-吡啶基）氨基）乙氧基]苄基]噻唑烷-2,4-二酮的马来酸盐的水合物，其特征在于：（i）包含 水的范围为0.2〜1.1％w / w; 和（ii）提供含有764和579cm -1的峰的红外光谱; 和/或（iii）提供基本如图1所示的X射线粉末衍射（XRPD）图案。 二 制备这种化合物的方法，含有这种化合物的药物组合物和这种化合物或组合物在医药中的用途。

    Quartz crystal microbalance with feedback loop for automatic gain control
    35.
    发明申请
    Quartz crystal microbalance with feedback loop for automatic gain control 有权
    具有反馈回路的石英晶体微量天平，用于自动增益控制

    公开(公告)号：US20040020275A1

    公开(公告)日：2004-02-05

    申请号：US10630072

    申请日：2003-07-30

    Applicant: SmithKline Beecham p.l.c.

    Inventor： Frank Paul ,  Karl Pavey ,  Richard C. Payne

    IPC: G01N029/02

    CPC classification number: G01N29/036 ,  G01G3/13 ,  G01N2291/0256

    Abstract: An analytical apparatus, such as a quartz crystal microbalance, comprising a piezoelectric sensor and an oscillator circuit, coupled to the sensor, to oscillate at a frequency substantially determined by a resonant frequency of the sensor, and to provide an output signal at the oscillator frequency at an output, the oscillator circuit incorporates means to maintain a substantially constant drive signal to the piezoelectric sensor. Preferably the substantially constant drive signal is maintained by AGC means (33) within a feedback loop of the oscillator. Advantageously the gain control signal is used as an indication of the Q of the piezoelectric sensor. It is desirable that the drive signal to the sensor is substantially sinusoidal since this provides greater accuracy, sensitivity and stability for the apparatus. This can be achieved by ensuring that all the elements in the feedback loop providing signal gain and attenuation are configured to operate in a substantially linear mode.

    Abstract translation: 诸如石英晶体微量天平的分析装置包括耦合到传感器的压电传感器和振荡器电路，以基本上由传感器的谐振频率确定的频率振荡，并且以振荡器频率提供输出信号 在输出端，振荡器电路包括为压电传感器维持基本恒定的驱动信号的装置。 优选地，基本恒定的驱动信号由振荡器的反馈回路内的AGC装置（33）保持。 有利地，增益控制信号用作压电传感器的Q的指示。 希望传感器的驱动信号基本上是正弦的，因为这为设备提供了更高的精度，灵敏度和稳定性。 这可以通过确保提供信号增益和衰减的反馈回路中的所有元件被配置为以基本上线性的方式工作来实现。

    Nitro-benzamide useful as anti-arrhythmic agent
    38.
    发明申请
    Nitro-benzamide useful as anti-arrhythmic agent 审中-公开
    硝基苯甲酰胺可用作抗心律失常剂

    公开(公告)号：US20030083524A1

    公开(公告)日：2003-05-01

    申请号：US10223872

    申请日：2002-08-20

    Applicant: SmithKline Beecham p.l.c.

    Inventor： Graham Ralph Slater ,  Paul Jeffrey Westlake

    IPC: C07C237/20

    CPC classification number: C07C233/78

    Abstract: Hydrated N-null3-nullnull2-(3,4-dimethoxyphenyl)ethylnullaminonullpropylnull-4-nitro benzamide hydrochloride characterized in that it: (i) comprises water in the range of from 1.7 to 2.4 molar equivalents; and/or (ii) has a melting point above 145null C. and/or (iii) provides an infra red spectrum containing peaks at 3510, 3342, 3076, 1665, 1598, 1343, 1330, 1216 and 801 cmnull1; and/or (iv) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as represented in Table I; and/or (v) provides an X-ray powder refraction (XRPD) pattern substantially as represented in Table II; a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine.

    Abstract translation: 水合N- [3 - [[2-（3,4-二甲氧基苯基）乙基]氨基]丙基] -4-硝基苯甲酰胺盐酸盐，其特征在于：（i）包含1.7-2.4摩尔当量的水; 和/或（ii）具有高于145℃的熔点和/或（iii）提供在3510,3422,3076,1665,1598,1343,1330,1216和801cm -1处含有峰的红外光谱; 和/或（iv）提供包含基本上如表I所示的化学位移的固态核磁共振光谱; 和/或（v）提供基本如表II所示的X射线粉末折射（XRPD）图案; 制备这种化合物的方法，包含这种化合物的药物组合物和这种化合物在医药中的用途。

    PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE
    39.
    发明申请
    PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE 失效
    制定印度衍生物的方法

    公开(公告)号：US20030083506A1

    公开(公告)日：2003-05-01

    申请号：US10308474

    申请日：2002-12-03

    Applicant: SmithKline Beecham p.l.c.

    Inventor： Michael Fedouloff ,  John Bryce Strachan

    IPC: C07D209/36

    CPC classification number: C07D209/42

    Abstract: A process for the preparation of methyl 2-(3-chloropropoxy)-indole-3-carboxylate, which comprises reacting a 3-chloro-3-carboxylate indole compound with 3-chloropropanol in the presence of an acid having a pKa of from 0 to 2.

    Abstract translation: 一种制备2-（3-氯丙氧基） - 吲哚-3-甲酸甲酯的方法，其包括使3-氯-3-羧酸吲哚化合物与3-氯丙醇在pKa为0的酸存在下反应 到2。

    Use of nitric oxide synthase inhibitors for the treatment of diabetes
    40.
    发明申请
    Use of nitric oxide synthase inhibitors for the treatment of diabetes 审中-公开
    使用一氧化氮合酶抑制剂治疗糖尿病

    公开(公告)号：US20030065036A1

    公开(公告)日：2003-04-03

    申请号：US10290133

    申请日：2002-11-07

    Applicant: SmithKline Beecham p.l.c.

    Inventor： Nicholas Charles Turner ,  Valerie Piercy

    IPC: A61K031/155

    CPC classification number: A61K31/198 ,  A61K31/00 ,  A61K31/155

    Abstract: A method for the treatment and/or prophylaxis of Type II diabetes, which method comprises the administration, to a human or non-human mammal, of an effective non-toxic pharmaceutically acceptable amount of an NO synthase inhibitor, such as aminoguanidine, or a pharmaceutically acceptable derivative thereof.

    Abstract translation: 一种治疗和/或预防II型糖尿病的方法，该方法包括向人或非人哺乳动物施用有效无毒的药学上可接受量的NO合酶抑制剂如氨基胍或 其药学上可接受的衍生物。

Patent Agency Ranking